Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Legend Biotech Corp ADR
(NQ:
LEGN
)
45.41
-0.52 (-1.13%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
689,465
Open
46.33
Bid (Size)
45.00 (7)
Ask (Size)
46.89 (20)
Prev. Close
45.93
Today's Range
45.24 - 46.81
52wk Range
42.08 - 77.32
Shares Outstanding
308,456,852
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
April 22, 2024
From
Legend Biotech Corporation
Via
Business Wire
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
April 19, 2024
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel
Via
Benzinga
Exposures
Product Safety
Performance
YTD
-23.16%
-23.16%
1 Month
-19.46%
-19.46%
3 Month
-18.56%
-18.56%
6 Month
-31.17%
-31.17%
1 Year
-32.26%
-32.26%
More News
Read More
Analyst Ratings For Legend Biotech
April 17, 2024
Via
Benzinga
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
April 11, 2024
From
Legend Biotech Corporation
Via
Business Wire
Unveiling 9 Analyst Insights On Legend Biotech
April 01, 2024
Via
Benzinga
Earnings Preview: Legend Biotech
March 08, 2024
Via
Benzinga
What 4 Analyst Ratings Have To Say About Legend Biotech
March 07, 2024
Via
Benzinga
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
April 08, 2024
Via
Benzinga
Exposures
Product Safety
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
April 05, 2024
From
Legend Biotech Corporation
Via
Business Wire
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy
March 20, 2024
Via
Benzinga
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
March 19, 2024
From
Legend Biotech Corporation
Via
Business Wire
FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
March 18, 2024
Via
Benzinga
Exposures
Product Safety
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
March 15, 2024
From
Legend Biotech Corporation
Via
Business Wire
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers
March 13, 2024
Via
Benzinga
Exposures
Product Safety
Beauty Health Posts Upbeat Sales, Joins SIGA Technologies, MaxCyte And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session
March 13, 2024
Via
Benzinga
Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights
March 11, 2024
From
Legend Biotech Corporation
Via
Business Wire
Earnings Scheduled For March 11, 2024
March 11, 2024
Via
Benzinga
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
March 09, 2024
Via
Talk Markets
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
March 07, 2024
Via
Benzinga
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership
February 24, 2024
Via
Talk Markets
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
February 23, 2024
From
Legend Biotech Corporation
Via
Business Wire
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results
February 13, 2024
From
Legend Biotech Corporation
Via
Business Wire
Focus On Bristol Myers, Gilead Sciences, Johnson & Johnson, Novartis: FDA To Issue Classwide Black Box Warning on CAR-T Therapies For Blood Cancer Treatment
January 23, 2024
Via
Benzinga
Exposures
Product Safety
As China's Population Declines In 2023, Will Aging Demographics Boost Healthcare Stocks?
January 10, 2024
Via
Benzinga
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
January 04, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.